Condition: Crohn's Disease · Sponsor: Takeda
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will receive vedolizumab only. Part B will include participants who responded to the treatment in Part A. Each participant will be followed up for at least 26 weeks after the last dose of treatment.
This description comes directly from the study's public registry record.
Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
Always discuss trial participation with your own doctor first.
| Digestive Health Specialsits | Dothan, Alabama, United States | Recruiting |
| GI Alliance Sun City | Sun City, Arizona, United States | Recruiting |
| University of California San Diego Health (UCSD) | La Jolla, California, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Hoag Hospital Newport Beach | Newport Beach, California, United States | Recruiting |
| Medical Research Center of Connecticut, LLC | Hamden, Connecticut, United States | Recruiting |
| Clinical Research of Osceola | Kissimmee, Florida, United States | Active Not Recruiting |
| Endoscopic Research Inc | Orlando, Florida, United States | Recruiting |
| Alliance Clinical Research of Tampa, LLC | Tampa, Florida, United States | Recruiting |
| Gastroenterology Consultants, P.C. | Roswell, Georgia, United States | Recruiting |
| University of Chicago Medicine | Chicago, Illinois, United States | Recruiting |
| GI Alliance - Illinois Gastroenterology Group - Glenview | Glenview, Illinois, United States | Recruiting |
+ 41 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06045754